Finch Therapeutics Group, Inc. — fact timeline

Finch Therapeutics Group, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(1)(C)).

“May 14, 2024, the Nasdaq Listing Qualifications Department issued an Additional Staff Determination that the Company’s continued noncompliance with the MVPHS Rule serves as an additional basis for delisting the Common Stock from The Nasdaq Global Select Market. Also as previously disclosed, the Company previously received a determination letter from the Nasdaq Listing Qualifications Department informing the Company of Nasdaq’s belief that the Company is a “public shell” under the Nasdaq criteria. The Company appealed the Nasdaq Listing Qualifications Department’s determination with respect to”

Finch Therapeutics Group, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)).

“April 2, 2024, the Company received a notice from Nasdaq acknowledging the fact that the Company does not meet the requirements of such rules. In accordance with Nasdaq Listing Rule 5605(c)(4) and the Nasdaq notice, to regain compliance with the Nasdaq Listing Rules, the Company has until the earlier of March 26, 2025 or its next annual stockholders meeting (or, if the next annual stockholders meeting is held before September 23, 2024, until September 23, 2024) to regain compliance with the Nasdaq Listing Rules related to audit committee composition. SIGNATURES Pursuant to the requirements of”

Finch Therapeutics Group, Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

“February 16, 2024, Finch Therapeutics Group, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based on the Staff’s review of the Company and pursuant to Listing Rule 5101, the Staff believes that the Company no longer has an operating business and is a “public shell” and that the continued listing of its securities is no longer warranted. The Company disagrees with Nasdaq’s determination regarding the Company’s status as a “public shell” and, accordingly, has requested an appeal hearing. The hearing request”

Finch Therapeutics Group, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C)).

“November 15, 2023, Finch Therapeutics Group, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 35 consecutive business days, it did not meet the requirement to have a market value of publicly held shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), of $5.0 million pursuant to Nasdaq Listing Rule 5450(b)(1)(C) (the “MVPHS Rule”). The deficiency letter has no immediate effect on the listing of the Common Stock on the Nasdaq Global Select”

Finch Therapeutics Group, Inc. terminated Lease with NRL WCS 200 Inner Belt Prop, LLC (effective 2023-06-30).

“In accordance with the terms of the Termination Agreement, the Landlord executed a new lease agreement with a third-party tenant for the Premises, and as a result, the Lease terminated on June 30, 2023.”

Nicholas Haft resigned as Director at Finch Therapeutics Group, Inc..

“On June 21, 2023, Nicholas Haft resigned from the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”), effective as of June 23, 2023.”

Finch Therapeutics Group, Inc.: Reverse stock split of common stock at a ratio of 1-for-30 (effective 2023-06-09).

“On June 9, 2023, Finch Therapeutics Group, Inc. (the “Company”) filed a Certificate of Amendment (the “Charter Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 (the “Common Stock”), at a ratio of 1-for-30.”

Finch Therapeutics Group, Inc. shareholders approved To approve the Charter Amendment to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of 1-for-30. at the 2023-06-08 meeting.

“To approve the Charter Amendment to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of 1-for-30. Votes For Votes Against Abstentions Broker Non-Votes 40,212,819 717,495 4,374 0”

Finch Therapeutics Group, Inc. shareholders approved Election of two nominees as Class II directors: Susan Graf and Chris Shumway at the 2023-06-08 meeting.

“To elect two nominees as Class II directors: Susan Graf and Chris Shumway, each to hold office until the Annual Meeting of Stockholders in 2026. Nominee Votes For Votes Withheld Broker Non-Votes Susan Graf 26,097,717 4,226,794 10,610,177 Chris Shumway 24,013,503 6,311,008 10,610,177”

Finch Therapeutics Group, Inc. terminated Lease Termination Agreement with NRL WCS 200 Inner Belt Prop, LLC (effective 2023-05-12).

“On May 12, 2023, Finch Therapeutics Group, Inc. (the “Company”) entered into a Lease Termination Agreement (the “Agreement”) with NRL WCS 200 Inner Belt Prop, LLC, a Delaware limited liability company (the “Landlord”), related to the office lease agreement”

Finch Therapeutics Group, Inc. engaged Wolf & Company, P.C. as its auditor.

“Also on May 8, 2023, the Audit Committee approved the engagement, effective May 12, 2023, of Wolf & Company, P.C. (“Wolf”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”

Finch Therapeutics Group, Inc. dismissed Deloitte & Touche LLP as its auditor.

“On May 8, 2023, the Audit Committee of the Board of Directors (the “Audit Committee”) of Finch Therapeutics Group, Inc. (the “Company”) approved the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective May 12, 2023.”

Finch Therapeutics Group, Inc. reported first quarter of 2023 results: net income net loss of $63.9 million.

“Finch reported a net loss of $63.9 million for the first quarter of 2023, compared to a net loss of $24.6 million for the same period in 2022.”

Lance Thibault was appointed as Chief Financial Officer at Finch Therapeutics Group, Inc..

“and Lance Thibault to serve as the Company’s Chief Financial Officer.”

Matthew P. Blischak was appointed as Chief Executive Officer at Finch Therapeutics Group, Inc..

“Additionally, on April 21, 2023, and effective as of May 16, 2023, the Board appointed Matthew P. Blischak to serve as the Company’s Chief Executive Officer”

Marc Blaustein was terminated as Chief Operating Officer at Finch Therapeutics Group, Inc..

“On April 21, 2023, the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”) approved the termination of employment, without cause, of each of Mark Smith, Ph.D., and Marc Blaustein, the Company’s Chief Executive Officer and Chief Operating Officer, in each case effective May 15, 2023.”

Mark Smith resigned as Director at Finch Therapeutics Group, Inc..

“Further, on April 21, 2023, Dr. Smith resigned as a member of the Board, effective as of May 15, 2023.”

Mark Smith was terminated as Chief Executive Officer at Finch Therapeutics Group, Inc..

“On April 21, 2023, the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”) approved the termination of employment, without cause, of each of Mark Smith, Ph.D., and Marc Blaustein, the Company’s Chief Executive Officer and Chief Operating Officer, in each case effective May 15, 2023.”

Finch Therapeutics Group, Inc. amended Amended and Restated Exclusive License Agreement with Regents of the University of Minnesota valued at amended terms related to performance milestones, including extension of deadlines and expansion of r (effective 2023-04-12).

“On April 12, 2023, Finch Therapeutics Holdings LLC (“FTH”), a direct, wholly owned subsidiary of Finch Therapeutics Group, Inc. (the “Company”), and the Regents of the University of Minnesota (“UMN”), entered into an amendment (the “Amendment”) to the Amended and Restated Exclusive License Agreement, dated January 28, 2022, between FTH and UMN (the “UMN Agreement”).”

Finch Therapeutics Group, Inc. reported the full year of 2022 results: net income $114.6 million.

“Finch reported a net loss of $114.6 million for the full year of 2022”

Finch Therapeutics Group, Inc. reported the fourth quarter of 2022 results: net income $27.0 million.

“Finch reported a net loss of $27.0 million for the fourth quarter of 2022”

Finch Therapeutics Group, Inc. terminated Loan and Security Agreement with Hercules Capital, Inc. as administrative agent and collateral agent for the Lenders valued at $16.2 million (effective 2023-01-25).

“On January 25, 2023, Finch Therapeutics Group, Inc. (the “Company”) provided notice of its intention to voluntarily prepay all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to $16.2 million in the aggregate (the “Payoff Amount”), under the Loan and Security Agreement (the “Loan Agreement”), dated as of May 11, 2022, by and among the Company and each of its subsidiaries, the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, the “Lenders”), and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the Lenders.”

Finch Therapeutics Group, Inc. announced a restructuring with charges of approximately $4.1 million (reduction of the Company’s workforce by 77 full-time employees, or approximately 95% of the Company’s current employee b).

“On January 24, 2023, Finch Therapeutics Group, Inc. (the “Company”) announced decisions to discontinue its Phase 3 clinical trial of CP101 in recurrent C. difficile infection and to focus on realizing the value of its intellectual property estate and other assets. In connection with these decisions, on January 23, 2023, the Company’s board of directors approved certain expense reduction measures, including a reduction of the Company’s workforce by 77 full-time employees, or approximately 95% of the Company’s current employee base (the “Restructuring”). The Company initiated the Restructuring on January 24, 2023, with the majority of impacted positions ending in February 2023 and a small portion of positions maintained into May 2023. As a result of the Restructuring, the Company estimates that it will incur approximately $4.1 million in costs resulting from cash expenditures consisting of one-time severance payments, outplacement services and related expenses.”

Finch Therapeutics Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 30, 2022, Finch Therapeutics Group, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $ 0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The deficiency letter has no immediate effect on the”

Marc Blaustein changed role as Chief Operating Officer at Finch Therapeutics Group, Inc..

“Additionally, on December 7, 2022, the Company entered into a Retention Bonus Agreement with Marc Blaustein, the Company’s Chief Operating Officer, who will also take over business development and investor relations responsibilities following Mr. Vittiglio’s resignation.”

Joseph Vittiglio resigned as Chief Business and Legal Officer and Secretary at Finch Therapeutics Group, Inc..

“On December 7, 2022, Joseph Vittiglio informed Finch Therapeutics Group, Inc. (the “Company”) of his resignation as the Company’s Chief Business and Legal Officer and Secretary, effective as of December 31, 2022, in order to pursue other professional opportunities.”

Finch Therapeutics Group, Inc. reported third quarter ended September 30, 2022 results: revenue $11.2 million, net income ($40.4 million).

“net loss was driven by a charge of $18.1 million for the full impairment of the Company’s goodwill during the current quarter. Additionally, there was a decrease in revenue of $11.2 million due to changes under Finch’s collaboration agreement with Takeda, including Takeda’s election in August 2022 to terminate the agreement. Finch also reported an increase in”

Samuel Allen Hamood was elected as Director at Finch Therapeutics Group, Inc..

“elected Samuel Allen Hamood to the Board, effective immediately, to serve as a Class I director”

Marc Blaustein was appointed as Chief Operating Officer at Finch Therapeutics Group, Inc..

“appointed Marc Blaustein to serve as the Company’s Chief Operating Officer, effective September 8, 2021.”